Proactive Investors - Run By Investors For Investors

Judges Scientific nudges higher as it buys niche lighting group

The expansion of instrument maker Judges Scientific continues, with the acquisition of CooLED - a niche LED microscopy lighting firm...
Judges Scientific nudges higher as it buys niche lighting group
A fluorescent image of a rat liver taken using CoolLED technology...

The expansion of instrument maker Judges Scientific (LON:JDG) continues, with a potentially immediately earnings enhancing acquisition of CooLED - a niche LED microscopy lighting firm - for an initial cash sum of £3.5mln.

CoolLED is based in Andover, Hants, and specialises in making illumination systems for fluorescence microscopy -  a growing niche of the life-sciences market.

LED lights are now gradually replacing conventional mercury based lighting systems in new and existing installations.

Judges chairman Alex Hambro told investors: "CoolLED is a world class company, with an excellent reputation in its niche market within the life-sciences sector, and its positive impact on the Group's financial performance should be immediate.

"We are delighted to welcome Jim Beacher and his colleagues to the group's management team."

In the year to June 30, 2015, CoolLED posted  revenues of £2.5 million and pre-tax profits of £0.5 million.

Judges bought CooLED for an initial cash consideration of £3.5 million with an earn-out capped at £1mln.

The earn-out may be payable subject to CoolLED generating adjusted operating profits of over £1 million for the year to June 30, 2016, reducing by £4.50 for each £1 shortfall below £1 million.

Judges shares added 2.5% to stand at 1.540p.

View full JDG profile View Profile

Judges Scientific Timeline

CN Research
March 22 2018

Related Articles

couple looking at pregnancy test
November 13 2017
The proceeds from the fundraiser will be used to expand in the People's Republic and will invested in product development
profit meter
April 02 2018
Having secured US$6.9mln of new investment, the company is now primed for growth
numerous pills
March 23 2018
Genervon is on the lookout for pharma partners to help advance its GM6 drug, which takes aim at a range of deadly diseases hitting the central nervous system

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use